EC ap­proves Ab­b­Vie's upadac­i­tinib as first JAK in­hibitor for atopic der­mati­tis

Un­like the FDA, the Eu­ro­pean Com­mis­sion isn’t hes­i­tat­ing be­fore hand­ing mar­ket­ing au­tho­riza­tion to Rin­voq as the first JAK in­hibitor to treat mod­er­ate and se­vere atopic der­mati­tis — eczema — among adults and ado­les­cents. The green light ar­rived Tues­day morn­ing.

Rin­voq’s ap­proval al­lows the drug to be mar­ket­ed and sold in all mem­ber states of the Eu­ro­pean Union, plus a se­lect few oth­er Eu­ro­pean na­tions such as Ice­land and Nor­way.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER